Cargando…

Sideroblastic anemia: functional study of two novel missense mutations in ALAS2

BACKGROUND: X‐linked sideroblastic anemia (XLSA) is a disorder characterized by decreased heme synthesis and mitochondrial iron overload with ringed sideroblasts in bone marrow. XLSA is caused by mutations in the erythroid‐specific gene coding 5‐aminolevulinate synthase (ALAS2). Anemia in XLSA is ex...

Descripción completa

Detalles Bibliográficos
Autores principales: Méndez, Manuel, Moreno‐Carralero, María‐Isabel, Morado‐Arias, Marta, Fernández‐Jiménez, María‐Cristina, de la Iglesia Iñigo, Silvia, Morán‐Jiménez, María‐José
Formato: Online Artículo Texto
Lenguaje:English
Publicado: John Wiley and Sons Inc. 2016
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4867561/
https://www.ncbi.nlm.nih.gov/pubmed/27247955
http://dx.doi.org/10.1002/mgg3.202
_version_ 1782432042144759808
author Méndez, Manuel
Moreno‐Carralero, María‐Isabel
Morado‐Arias, Marta
Fernández‐Jiménez, María‐Cristina
de la Iglesia Iñigo, Silvia
Morán‐Jiménez, María‐José
author_facet Méndez, Manuel
Moreno‐Carralero, María‐Isabel
Morado‐Arias, Marta
Fernández‐Jiménez, María‐Cristina
de la Iglesia Iñigo, Silvia
Morán‐Jiménez, María‐José
author_sort Méndez, Manuel
collection PubMed
description BACKGROUND: X‐linked sideroblastic anemia (XLSA) is a disorder characterized by decreased heme synthesis and mitochondrial iron overload with ringed sideroblasts in bone marrow. XLSA is caused by mutations in the erythroid‐specific gene coding 5‐aminolevulinate synthase (ALAS2). Anemia in XLSA is extremely variable, characteristically microcytic and hypochromic with poikilocytosis, and the red blood cell distribution width is increased and prominent dimorphism of the red cell population. Anemia in XLSA patients responds variably to supplementation with pyridoxine. METHODS AND RESULTS: We report four patients with XLSA and three mutations in ALAS2: c.611G>A (p.Arg204Gln), c.1218G>T (p.Leu406Phe) and c.1499A>G (p.Tyr500Cys). The in silico predictions of three ALAS2 mutations and the functional consequences of two ALAS2 mutations were assessed. We performed in silico analysis of these mutations using ten different softwares, and all of them predicted that the p.Tyr500Cys mutation was deleterious. The in vitro prokaryotic expression showed that the p.Leu406Phe and p.Tyr500Cys mutations reduced the ALAS2 specific activity (SA) to 14% and 7% of the control value, respectively. CONCLUSION: In view of the results obtained in this study, a clear relationship between genotype and phenotype cannot be established; clinical variability or severity of anemia may be influenced by allelic variants in other genes or transcription factors and environmental conditions.
format Online
Article
Text
id pubmed-4867561
institution National Center for Biotechnology Information
language English
publishDate 2016
publisher John Wiley and Sons Inc.
record_format MEDLINE/PubMed
spelling pubmed-48675612016-05-31 Sideroblastic anemia: functional study of two novel missense mutations in ALAS2 Méndez, Manuel Moreno‐Carralero, María‐Isabel Morado‐Arias, Marta Fernández‐Jiménez, María‐Cristina de la Iglesia Iñigo, Silvia Morán‐Jiménez, María‐José Mol Genet Genomic Med Original Articles BACKGROUND: X‐linked sideroblastic anemia (XLSA) is a disorder characterized by decreased heme synthesis and mitochondrial iron overload with ringed sideroblasts in bone marrow. XLSA is caused by mutations in the erythroid‐specific gene coding 5‐aminolevulinate synthase (ALAS2). Anemia in XLSA is extremely variable, characteristically microcytic and hypochromic with poikilocytosis, and the red blood cell distribution width is increased and prominent dimorphism of the red cell population. Anemia in XLSA patients responds variably to supplementation with pyridoxine. METHODS AND RESULTS: We report four patients with XLSA and three mutations in ALAS2: c.611G>A (p.Arg204Gln), c.1218G>T (p.Leu406Phe) and c.1499A>G (p.Tyr500Cys). The in silico predictions of three ALAS2 mutations and the functional consequences of two ALAS2 mutations were assessed. We performed in silico analysis of these mutations using ten different softwares, and all of them predicted that the p.Tyr500Cys mutation was deleterious. The in vitro prokaryotic expression showed that the p.Leu406Phe and p.Tyr500Cys mutations reduced the ALAS2 specific activity (SA) to 14% and 7% of the control value, respectively. CONCLUSION: In view of the results obtained in this study, a clear relationship between genotype and phenotype cannot be established; clinical variability or severity of anemia may be influenced by allelic variants in other genes or transcription factors and environmental conditions. John Wiley and Sons Inc. 2016-01-13 /pmc/articles/PMC4867561/ /pubmed/27247955 http://dx.doi.org/10.1002/mgg3.202 Text en © 2016 The Authors. Molecular Genetics & Genomic Medicine published by Wiley Periodicals, Inc. This is an open access article under the terms of the Creative Commons Attribution (http://creativecommons.org/licenses/by/4.0/) License, which permits use, distribution and reproduction in any medium, provided the original work is properly cited.
spellingShingle Original Articles
Méndez, Manuel
Moreno‐Carralero, María‐Isabel
Morado‐Arias, Marta
Fernández‐Jiménez, María‐Cristina
de la Iglesia Iñigo, Silvia
Morán‐Jiménez, María‐José
Sideroblastic anemia: functional study of two novel missense mutations in ALAS2
title Sideroblastic anemia: functional study of two novel missense mutations in ALAS2
title_full Sideroblastic anemia: functional study of two novel missense mutations in ALAS2
title_fullStr Sideroblastic anemia: functional study of two novel missense mutations in ALAS2
title_full_unstemmed Sideroblastic anemia: functional study of two novel missense mutations in ALAS2
title_short Sideroblastic anemia: functional study of two novel missense mutations in ALAS2
title_sort sideroblastic anemia: functional study of two novel missense mutations in alas2
topic Original Articles
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4867561/
https://www.ncbi.nlm.nih.gov/pubmed/27247955
http://dx.doi.org/10.1002/mgg3.202
work_keys_str_mv AT mendezmanuel sideroblasticanemiafunctionalstudyoftwonovelmissensemutationsinalas2
AT morenocarraleromariaisabel sideroblasticanemiafunctionalstudyoftwonovelmissensemutationsinalas2
AT moradoariasmarta sideroblasticanemiafunctionalstudyoftwonovelmissensemutationsinalas2
AT fernandezjimenezmariacristina sideroblasticanemiafunctionalstudyoftwonovelmissensemutationsinalas2
AT delaiglesiainigosilvia sideroblasticanemiafunctionalstudyoftwonovelmissensemutationsinalas2
AT moranjimenezmariajose sideroblasticanemiafunctionalstudyoftwonovelmissensemutationsinalas2